Fig. 2
From: High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer
Relationship of RIPK2 expression with survival outcome. A Overall survival (OS) and progression-free interval (PFI) in RIPK2 high and low expression groups in the TCGA-OV dataset. B Overall survival (OS) and progression-free interval (PFI) in the RIPK2 high and low expression groups in the GSE30161 dataset. C Overall survival (OS) and progression-free interval (PFI) in the RIPK2 high and low expression groups in the GSE32063 dataset. D Overall survival (OS) and progression-free interval (PFI) in the RIPK2 high and low expression group in the GSE63885 dataset. E Overall survival (OS) of groups defined by RIPK2 expression and Taxol usage in the TCGA-OV cohort. The numbers below the figures denote the number of patients at risk in each group